scholarly journals Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis

2009 ◽  
Vol 60 (5) ◽  
pp. 1519-1529 ◽  
Author(s):  
Hossein Hemmatazad ◽  
Hanna Maciejewska Rodrigues ◽  
Britta Maurer ◽  
Fabia Brentano ◽  
Margarita Pileckyte ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Histone Deacetylase ◽  
Potential Target

scholarly journals Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis

Autoimmunity ◽  
2009 ◽  
Vol 42 (2) ◽  
pp. 120-125 ◽  
Author(s):  
Yutaka Kuwatsuka ◽  
Fumihide Ogawa ◽  
Yohei Iwata ◽  
Kazuhiro Komura ◽  
Eiji Muroi ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Histone Deacetylase ◽  
Histone Deacetylase 3

Decreased Acetylation of Histone H3 in Renal Cell Carcinoma: A Potential Target of Histone Deacetylase Inhibitors

2008 ◽  
Vol 180 (3) ◽  
pp. 1131-1136 ◽  
Author(s):  
Kent Kanao ◽  
Shuji Mikami ◽  
Ryuichi Mizuno ◽  
Toshiaki Shinojima ◽  
Masaru Murai ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Histone Deacetylase ◽  
Renal Cell ◽  
Histone Deacetylase Inhibitors ◽  
Histone H3 ◽  
Potential Target

scholarly journals Tescalcin is a potential target of class I histone deacetylase inhibitors in neurons

2017 ◽  
Vol 482 (4) ◽  
pp. 1327-1333 ◽  
Author(s):  
Gakuya Takamatsu ◽  
Chiaki Katagiri ◽  
Tsumuraya Tomoyuki ◽  
Chigusa Shimizu-Okabe ◽  
Wakako Nakamura ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Class I ◽  
Potential Target

scholarly journals Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients

Blood ◽  
2017 ◽  
Vol 130 (19) ◽  
pp. 2073-2083 ◽  
Author(s):  
Benoit M. Cyrenne ◽  
Julia M. Lewis ◽  
Jason G. Weed ◽  
Kacie R. Carlson ◽  
Fatima N. Mirza ◽  
...  
Keyword(s):  
T Cell ◽  
Histone Deacetylase ◽  
Cell Lymphoma ◽  
Leukemic Cells ◽  
Cutaneous T Cell Lymphoma ◽  
Histone Deacetylase Inhibition ◽  
Antiapoptotic Protein ◽  
Potential Target ◽  
Synergistic Activation ◽  
Key Points

Key PointsThe antiapoptotic protein BCL2 is a promising potential target in the treatment of CTCL. Combination inhibition of BCL2 and HDACs leads to efficient killing of CTCL cells due to the synergistic activation of apoptosis.

scholarly journals Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis

2019 ◽  
Vol 72 (1) ◽  
pp. 137-149 ◽  
Author(s):  
Alina Soare ◽  
Hermina A. Györfi ◽  
Alexandru E. Matei ◽  
Clara Dees ◽  
Simon Rauber ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Potential Target ◽  
Dipeptidylpeptidase 4 ◽  
Activated Fibroblasts
Sign in / Sign up

Export Citation Format

Share Document